Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ESPB for Pain Control in ED
NCT05794828Phase 1Completed
- Sponsor
- UT Health San Antonio
- Start
- Sep 2023
- Primary completion
- Feb 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of bupivacaine hydrochloride 0.75% injection in rib fracture, Vertebral fracture, pancreatitis and 3 more, sponsored by UT Health San Antonio. Primary endpoint: Numeric Pain Rating Scale at 30 months. Started Sep 2023; status: completed.
02
Drugs
bupivacaine hydrochloride 0.75% injection
03
Conditions
rib fractureVertebral fracturepancreatitispancreatic cancer (PC)Renal colic
Beyond the preview
Go deeper on NCT05794828.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05794828.